Bacterial pneumonia
Drug research and approvals for bacterial pneumonia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 56 studies of bacterial pneumonia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 56
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- Effect of Ventilator Hyperinflation Combined With Body Positioning on ABG in VAPNCT07854730 · Not applicable · Al-Zaytoonah University of Jordan · starts Oct 5, 2026
- ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaNCT07759934 · Phase 2 · Jiangsu Aosaikang Pharmaceutical Co., Ltd. · starts Mar 25, 2026
- Lefamulin Post-Market Surveillance StudyNCT07697885 · Not reported · Marubeni Pharmaceuticals (Suzhou) Co., Ltd. · starts Jun 30, 2026
- Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor ScoreNCT07681583 · Not reported · Azienda Ospedaliero-Universitaria Careggi · starts Nov 13, 2025
- BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics and RadiomicsNCT07633366 · Not reported · Medical University of Vienna · starts Jul 1, 2026
- Impact of BioFire FilmArray Pneumonia Panel vs Routine Diagnostics on Antimicrobial Outcomes (DOOR-MAT)NCT07585604 · Not applicable · Hospital de Clinicas de Porto Alegre · starts May 20, 2026
- Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired…NCT07512596 · Phase 2 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · starts Jul 21, 2026
- MP101 in Adults With Acute Pseudomonas Aeruginosa PneumoniaNCT07492771 · Phase 1 · MicrobiotiX Co., Ltd · starts Jul 25, 2026
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveNCT07358910 · Not reported · Institut Pasteur du Cambodge · starts Dec 18, 2025
Approved 8
- TelavancinCell outer membrane inhibitor
- Ceftaroline fosamilBacterial penicillin-binding protein inhibitor
- OmadacyclineBacterial 70S ribosome inhibitor
- CefiderocolBacterial penicillin-binding protein inhibitor
- TelithromycinBacterial 70S ribosome inhibitor
- ErtapenemBacterial penicillin-binding protein inhibitor
- DoripenemBacterial penicillin-binding protein inhibitor
- LefamulinBacterial 70S ribosome inhibitor
Phase 3 12 of 22
- MoxifloxacinTopoisomerase IV inhibitor
- AmikacinBacterial 70S ribosome inhibitor
- TigecyclineBacterial 70S ribosome inhibitor
- CilastatinRenal dipeptidase inhibitor
- CeftriaxoneBacterial penicillin-binding protein inhibitor
- ImipenemBacterial penicillin-binding protein inhibitor
- LinezolidBacterial 70S ribosome inhibitor
- Solithromycin
- VancomycinPeptidoglycan inhibitor
- MeropenemBacterial penicillin-binding protein inhibitor
- LevofloxacinDNA gyrase inhibitor
- TazobactamBacterial beta-lactamase TEM inhibitor
Phase 2 9
- FosfomycinUDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor
- GentamicinBacterial 70S ribosome inhibitor
- Tobramycin70S ribosome inhibitor
- Methylprednisolone hemisuccinateGlucocorticoid receptor agonist
- Clavulanic acidBacterial beta-lactamase TEM inhibitor
- AmoxicillinBacterial penicillin-binding protein inhibitor
- SulopenemBacterial penicillin-binding protein inhibitor
- AcorafloxacinBacterial DNA gyrase inhibitor
- NafithromycinBacterial 70S ribosome inhibitor
Phase 1 or earlier 1
How its trials ended
143 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 50 whose ending is known, 52% met their primary endpoint, 8% missed it and 40% stopped early.
- Completed, result not reported5941%
- Met its primary endpoint2618%
- Ongoing1813%
- Status unknown1611%
- Stopped: other or unclear128%
- Stopped: enrollment or feasibility64%
- Missed its primary endpoint43%
- Stopped: lack of efficacy11%
- Stopped: sponsor or business decision11%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Sep 28, 2017 | A multicenter, randomized, double-blind, parallelgroup, clinical study of S-649266 compared with meropenem for the treatment of hospital-acquired bacterial…Cefiderocol (S-649266)/ Meropenem | Shionogi | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA